OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SRRK$48.0057

SRRK.O

Biotechnology & Medical ResearchVerified

SRRK.O has a high liquidity position, with cash and equivalents amounting to $323.5 million, which is significantly higher than its total liabilities of $158.8 million, resulting in a current ratio of 6.95. The company's price-to-book ratio is 23.33, indicating a high valuation relative to its book value. The company is currently unprofitable, with a net loss of $377.9 million and an operating loss of $384.6 million, resulting in a negative return on equity of -1.54 and a negative return on assets of -0.93. These figures are below the industry norms for profitability and returns, suggesting underperformance relative to its peers. SRRK.O's revenue is not segmented by geographic region or product line in the provided data, so it is not possible to determine the geographic or segment concentration of its revenue. The company's growth trajectory is not explicitly provided, but the negative operating and net income suggest a challenging growth environment. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.41, suggesting a relatively conservative capital structure. Recent events related to SRRK.O are not detailed in the provided data, so no specific recent filings or transcripts can be cited.

30-day price · SRRK-0.18 (-0.4%)
Low$45.00High$52.19Close$49.82As of29 May, 00:00 UTC
Profile
CompanySRRK.O
TickerSRRK.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. SRRK.O is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of biotech products.

Classification. SRRK.O is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

SRRK.O has a high liquidity position, with cash and equivalents amounting to $323.5 million, which is significantly higher than its total liabilities of $158.8 million, resulting in a current ratio of 6.95. The company's price-to-book ratio is 23.33, indicating a high valuation relative to its book value. The company is currently unprofitable, with a net loss of $377.9 million and an operating loss of $384.6 million, resulting in a negative return on equity of -1.54 and a negative return on assets of -0.93. These figures are below the industry norms for profitability and returns, suggesting underperformance relative to its peers. SRRK.O's revenue is not segmented by geographic region or product line in the provided data, so it is not possible to determine the geographic or segment concentration of its revenue. The company's growth trajectory is not explicitly provided, but the negative operating and net income suggest a challenging growth environment. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.41, suggesting a relatively conservative capital structure. Recent events related to SRRK.O are not detailed in the provided data, so no specific recent filings or transcripts can be cited.
Key takeaways
  • SRRK.O has a strong liquidity position with a current ratio of 6.95.
  • The company is currently unprofitable with a net loss of $377.9 million.
  • SRRK.O's price-to-book ratio is 23.33, indicating a high valuation relative to its book value.
  • The company has a low debt-to-equity ratio of 0.41, suggesting a conservative capital structure.
  • Analysts have a positive outlook on SRRK.O, with a mean price target of $58.29 and a mean recommendation of 1.59.
  • # RATIONALES
  • margin_outlook_rationale: The company's negative operating and net income suggest a challenging margin outlook driven by high operating costs and lack of revenue growth.
  • rd_outlook_rationale: No specific R&D outlook is provided, but the company's focus on biotechnology implies ongoing R&D investment.
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue
Gross profit
Operating income-$384.6M
Net income-$377.9M
R&D
SG&A
D&A
SBC
Operating cash flow-$300.0M
CapEx-$602.0k
Free cash flow-$376.8M
Total assets$404.3M
Total liabilities$158.8M
Total equity$245.5M
Cash & equivalents$323.5M
Long-term debt$99.7M
Valuation
Market price$48.00
Market cap$5.73B
Enterprise value$5.50B
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B23.3
P/Tangible book23.3
Tangible book$245.5M
Net cash$223.8M
Current ratio7.0
Debt/Equity0.4
ROA-93.5%
ROE-1.5%
Cash conversion79.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricSRRKActivity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity41.0%9.3% medp25 0.1% · p75 43.8%above median
Observations
IR observations
Mean price target58.29 USD
Median price target58.00 USD
High price target70.00 USD
Low price target48.00 USD
Mean recommendation1.59 (1=strong buy, 5=strong sell)
Strong-buy count7.00
Buy count10.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-3.20 USD
Last actual EPS-3.29 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 21:25 UTC#727a5a08
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 13:42 UTCJob: da8224c9